In the News

Researchers at Johns Hopkins test paroxetine on developing brain cells and discover numerous neurotoxic effects.

A new update to the NICE guideline for depression suggests providers discuss long-term, severe antidepressant withdrawal symptoms.

A study published in the journal Pediatrics reveals large differences from one pediatrician to the next when it comes to diagnosing and prescribing drugs for ‘ADHD.’ The researchers found that the percentage of children being diagnosed with ‘ADHD’ varied from as high as 16% of patients at some offices to as little as 1% of patients at others. The data also revealed significant but lower variability in the pediatric diagnosis of anxiety and depression.

A new study, published in the JAMA Psychiatry, investigates the effect of stimulant ‘ADHD’ drugs on the brains of children and young adults. The...

Three phase III clinical trials assessing the efficacy of Lundbeck’s investigational drug idalopirdine for Alzheimer’s disease have failed

Majority of top-selling and most promoted drugs in Canada are rated as having very limited safety and efficacy.

The August issue of Psychotherapy and Psychosomatics published a review conducted by André F. Carvalho and colleagues regarding the literature around the long-term use...

A new analysis, published in Lancet Neurology, demonstrates how Biogen is spinning results from two failed trials for a new Alzheimer's drug.

Primary care clinicians and mental health providers face a particular set of challenges when treating individuals with chronic pain. These problems are compounded by...

Previously taking antidepressants could make individuals less likely to respond to treatment for bipolar II depression.

A recent review of the evidence by the American College of Physicians (ACP) determined that cognitive behavioral therapy and antidepressants had similar levels of effectiveness for the treatment of depression. In a critical commentary for the Journal of Mental Health, however, Michael Sugarman from Wayne State University challenges these findings. Pointing to differences in research settings and clinical practice, Sugarman asserts that “these head-to-head comparisons are heavily biased in the direction of psychiatric care.”

A new study reports that the supplement EPA improved ADHD symptoms but a closer look calls these results into question.

Children who were exposed to anti-seizure drug valproate in utero were 48% more likely to develop ADHD, according to a new study.

A woman in Texas attempted suicide while in the active group of a clinical trial for smoking-cassation drugs Chantix and Zyban, both known to...

Accumulating evidence points to serious risks associated with antidepressant use during pregnancy, yet data suggests that prescriptions continue to rise in the US. "Given...

Analysis of longitudinal data from 2000-2014 demonstrate mortality gap is widening between persons with a diagnosis of bipolar or schizophrenia compared to the general population

Recent research implicates benzodiazepines as being involved in a high rate of emergency department visits in the US.

A study published in this month’s issue of the Journal of Clinical Psychiatry found that the use of antidepressant drugs was associated with an...

A new study explores how people manage to discontinue antipsychotic medication and examines how social supports may improve outcomes.

For the Conversation, Binghamton University researcher Lina Begdache tackles the issue of the growing use of 'Study Drugs' in the student population. “Animal studies show...

In a large review study published this week in The Lancet, researchers assessed the effectiveness and potential harms of fourteen different antidepressants for their use in children and adolescents. The negative results, familiar to MIA readers, are now making major headlines.

Review of a new mixed depression guideline reveals financial bias of guideline developers and lack of evidence supporting recommendations for prescribing of antipsychotics.

According to new research by Joanna Moncrieff and Sebastião Viola, mental health problems have become the leading cause of disability claims in the UK. While the overall number of claims for other conditions has decreased by 35%, claims related to “mental disorders” have increased 103% since 1995.

A new article documents the “flimsy evidence” behind the recent FDA approval of the party drug esketamine for the treatment of depression.

“The rising death rates for those young white adults, ages 25 to 34, make them the first generation since the Vietnam War years of the mid-1960s to experience higher death rates in early adulthood than the generation that preceded it,” the ‘Times reports.